ZA202002740B - Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione - Google Patents
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dioneInfo
- Publication number
- ZA202002740B ZA202002740B ZA2020/02740A ZA202002740A ZA202002740B ZA 202002740 B ZA202002740 B ZA 202002740B ZA 2020/02740 A ZA2020/02740 A ZA 2020/02740A ZA 202002740 A ZA202002740 A ZA 202002740A ZA 202002740 B ZA202002740 B ZA 202002740B
- Authority
- ZA
- South Africa
- Prior art keywords
- fluorobenzofuran
- dioxolo
- indol
- dione
- pyrrole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572603P | 2017-10-16 | 2017-10-16 | |
| PCT/US2018/056083 WO2019079299A1 (en) | 2017-10-16 | 2018-10-16 | SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202002740B true ZA202002740B (en) | 2025-12-17 |
Family
ID=64110166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/02740A ZA202002740B (en) | 2017-10-16 | 2020-05-13 | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11407759B2 (enExample) |
| EP (1) | EP3697794B1 (enExample) |
| JP (2) | JP7776258B2 (enExample) |
| KR (1) | KR102891811B1 (enExample) |
| CN (1) | CN111315748B (enExample) |
| AU (1) | AU2018352384B2 (enExample) |
| CA (1) | CA3074037A1 (enExample) |
| DK (1) | DK3697794T3 (enExample) |
| ES (1) | ES3064009T3 (enExample) |
| FI (1) | FI3697794T3 (enExample) |
| IL (1) | IL273920B2 (enExample) |
| MX (1) | MX2020003431A (enExample) |
| PL (1) | PL3697794T3 (enExample) |
| PT (1) | PT3697794T (enExample) |
| WO (1) | WO2019079299A1 (enExample) |
| ZA (1) | ZA202002740B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3697794T (pt) * | 2017-10-16 | 2026-03-04 | Actuate Therapeutics Inc | Formas sólidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona |
| EP3793545A4 (en) * | 2018-05-17 | 2022-04-06 | Actuate Therapeutics Inc. | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS WITH BETA INHIBITORS IN THE FORM OF GLYCOGEN SYNTHASE KINASE 3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2446269T3 (es) | 2006-12-19 | 2014-03-06 | The Board Of Trustees Of The University Of Illinois | 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos |
| CN111247153B (zh) | 2017-08-11 | 2024-04-02 | 开动疗法公司 | 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1，3]间二氧杂环戊烯并[4，5-f]吲哚-7-基)吡咯-2，5-二酮的固体形式 |
| PT3697794T (pt) * | 2017-10-16 | 2026-03-04 | Actuate Therapeutics Inc | Formas sólidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona |
-
2018
- 2018-10-16 PT PT187973672T patent/PT3697794T/pt unknown
- 2018-10-16 WO PCT/US2018/056083 patent/WO2019079299A1/en not_active Ceased
- 2018-10-16 ES ES18797367T patent/ES3064009T3/es active Active
- 2018-10-16 AU AU2018352384A patent/AU2018352384B2/en active Active
- 2018-10-16 MX MX2020003431A patent/MX2020003431A/es unknown
- 2018-10-16 CA CA3074037A patent/CA3074037A1/en active Pending
- 2018-10-16 IL IL273920A patent/IL273920B2/en unknown
- 2018-10-16 US US16/755,903 patent/US11407759B2/en active Active
- 2018-10-16 JP JP2020521319A patent/JP7776258B2/ja active Active
- 2018-10-16 FI FIEP18797367.2T patent/FI3697794T3/fi active
- 2018-10-16 KR KR1020207013947A patent/KR102891811B1/ko active Active
- 2018-10-16 EP EP18797367.2A patent/EP3697794B1/en active Active
- 2018-10-16 PL PL18797367.2T patent/PL3697794T3/pl unknown
- 2018-10-16 DK DK18797367.2T patent/DK3697794T3/da active
- 2018-10-16 CN CN201880066706.4A patent/CN111315748B/zh active Active
-
2020
- 2020-05-13 ZA ZA2020/02740A patent/ZA202002740B/en unknown
-
2022
- 2022-07-01 US US17/855,847 patent/US12116374B2/en active Active
-
2023
- 2023-09-19 JP JP2023151499A patent/JP2024001040A/ja active Pending
-
2024
- 2024-09-10 US US18/830,117 patent/US20250115615A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3064009T3 (en) | 2026-04-22 |
| BR112020007538A2 (pt) | 2020-09-24 |
| JP2020536944A (ja) | 2020-12-17 |
| KR102891811B1 (ko) | 2025-11-28 |
| PT3697794T (pt) | 2026-03-04 |
| IL273920A (en) | 2020-05-31 |
| IL273920B2 (en) | 2025-07-01 |
| AU2018352384A1 (en) | 2020-05-21 |
| WO2019079299A1 (en) | 2019-04-25 |
| DK3697794T3 (da) | 2026-02-02 |
| US20200239489A1 (en) | 2020-07-30 |
| JP2024001040A (ja) | 2024-01-09 |
| CN111315748B (zh) | 2023-06-27 |
| AU2018352384B2 (en) | 2023-12-21 |
| MX2020003431A (es) | 2020-07-29 |
| EP3697794A1 (en) | 2020-08-26 |
| US20250115615A1 (en) | 2025-04-10 |
| EP3697794B1 (en) | 2025-12-24 |
| KR20200100615A (ko) | 2020-08-26 |
| CN111315748A (zh) | 2020-06-19 |
| IL273920B1 (en) | 2025-03-01 |
| CA3074037A1 (en) | 2019-04-25 |
| PL3697794T3 (pl) | 2026-04-07 |
| JP7776258B2 (ja) | 2025-11-26 |
| US20220348591A1 (en) | 2022-11-03 |
| FI3697794T3 (fi) | 2026-02-10 |
| US12116374B2 (en) | 2024-10-15 |
| US11407759B2 (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521422031B1 (ar) | مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين | |
| PH12018500810A1 (en) | Antibody agents specific for human cd19 and uses thereof | |
| MY202018A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| MX2018009752A (es) | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| MY186217A (en) | Mixture of hmos | |
| UA108198C2 (uk) | Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| WO2019089676A8 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| GEP20247585B (en) | Furoindazole derivatives | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| MX379201B (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX2023005875A (es) | Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. | |
| EA201891611A1 (ru) | Роизводные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана | |
| EA201891612A1 (ru) | Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| MY150931A (en) | Substituted oxazolidinones and their use | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| ZA202002740B (en) | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MA32224B1 (fr) | Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales | |
| SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth | |
| MA32416B1 (fr) | 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation |